Sonnet BioTherapeutics (SONN) announced that the United States Patent and Trademark Office, USPTO, has issued U.S. Patent No. 12,134,635 entitled “Interleukin 18, IL-18, Variants and Fusion Proteins Comprising Same,” covering two of its novel drug candidates, SON-1411 and SON-1400, each containing a modified version of recombinant human interleukin-18. The patent carries a term effective until June 2044. “The issuance of this intellectual property is an important milestone that we believe provides significant differentiation from competitors trying to tap the full biological potential of IL-18, either alone or in combination with IL-12. IL-18 is a key cytokine that, when combined synergistically with IL-12, has the potential to be an important therapeutic asset for oncology and cell-based therapy,” commented Pankaj Mohan, Ph.D., Sonnet Founder and Chief Executive Officer.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on SONN:
- Sonnet BioTherapeutics files to sell common stock, warrants, no amount given
- Sonnet BioTherapeutics Maintains Nasdaq Listing Compliance
- Sonnet BioTherapeutics regains compliance with Nasdaq
- Sonnet BioTherapeutics’ Strategic Deal to Develop DPN Treatment
- Sonnet BioTherapeutics, Alkem enter licensing agreement for SON-080
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
